The Valley Desk

Clinical trial reportCancer chemotherapy and pharmacologyPublished

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Temple University, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer chemotherapy and pharmacology
Published
Subject terms
Humans; Neoplasms; Melanoma; Skin Neoplasms; Neoplasms, Second Primary; Proto-Oncogene Proteins B-raf; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Maximum Tolerated Dose; Adult; Braf; Phase 1
PubMed ID
37219686
PubMed Central ID
PMC10261210
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal